Compare ASH & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASH | WGS |
|---|---|---|
| Founded | 1924 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Specialty Chemicals | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2016 | N/A |
| Metric | ASH | WGS |
|---|---|---|
| Price | $57.93 | $69.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $65.57 | ★ $130.71 |
| AVG Volume (30 Days) | 568.1K | ★ 636.2K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,824,000,000.00 | N/A |
| Revenue This Year | $2.58 | $29.98 |
| Revenue Next Year | $4.28 | $25.92 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $46.30 | $55.17 |
| 52 Week High | $65.65 | $170.87 |
| Indicator | ASH | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 50.72 |
| Support Level | $47.40 | $68.55 |
| Resistance Level | $65.25 | $95.75 |
| Average True Range (ATR) | 1.56 | 4.23 |
| MACD | 0.61 | 1.45 |
| Stochastic Oscillator | 72.37 | 81.62 |
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.